health canada approval zepbound tirzepatide obesity canada 2024 2025 A 72-week trial compared the two leading GLP-1 medications in adults with (no diabetes). The results: β Tirzepatide: 20.2% weight loss β Semaglutide: 13.7% weight loss But weight loss isn't the π£ BIG NEWS IN OBESITY
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Sep 30 - Oct 5























